Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau
Janelidze, Shorena LU ; Palmqvist, Sebastian LU
; Leuzy, Antoine
LU
; Stomrud, Erik
LU
; Verberk, Inge M.W.
; Zetterberg, Henrik
LU
; Ashton, Nicholas J.
; Pesini, Pedro
; Sarasa, Leticia
and Allué, José Antonio
, et al.
(2022)
In Alzheimer's and Dementia
18(2).
p.283-293
- Abstract
Introduction: We studied usefulness of combining blood amyloid beta (Aβ)42/Aβ40, phosphorylated tau (p-tau)217, and neurofilament light (NfL) to detect abnormal brain Aβ deposition in different stages of early Alzheimer's disease (AD). Methods: Plasma biomarkers were measured using mass spectrometry (Aβ42/Aβ40) and immunoassays (p-tau217 and NfL) in cognitively unimpaired individuals (CU, N = 591) and patients with mild cognitive impairment (MCI, N = 304) from two independent cohorts (BioFINDER-1, BioFINDER-2). Results: In CU, a combination of plasma Aβ42/Aβ40 and p-tau217 detected abnormal brain Aβ status with area under the curve (AUC) of 0.83 to 0.86. In MCI, the models including p-tau217 alone or Aβ42/Aβ40 and p-tau217 had similar... (More)
Introduction: We studied usefulness of combining blood amyloid beta (Aβ)42/Aβ40, phosphorylated tau (p-tau)217, and neurofilament light (NfL) to detect abnormal brain Aβ deposition in different stages of early Alzheimer's disease (AD). Methods: Plasma biomarkers were measured using mass spectrometry (Aβ42/Aβ40) and immunoassays (p-tau217 and NfL) in cognitively unimpaired individuals (CU, N = 591) and patients with mild cognitive impairment (MCI, N = 304) from two independent cohorts (BioFINDER-1, BioFINDER-2). Results: In CU, a combination of plasma Aβ42/Aβ40 and p-tau217 detected abnormal brain Aβ status with area under the curve (AUC) of 0.83 to 0.86. In MCI, the models including p-tau217 alone or Aβ42/Aβ40 and p-tau217 had similar AUCs (0.86–0.88); however, the latter showed improved model fit. The models were implemented in an online application providing individualized risk assessments (https://brainapps.shinyapps.io/PredictABplasma/). Discussion: A combination of plasma Aβ42/Aβ40 and p-tau217 discriminated Aβ status with relatively high accuracy, whereas p-tau217 showed strongest associations with Aβ pathology in MCI but not in CU.
(Less)
- author
- Janelidze, Shorena
LU
; Palmqvist, Sebastian
LU
; Leuzy, Antoine
LU
; Stomrud, Erik
LU
; Verberk, Inge M.W.
; Zetterberg, Henrik
LU
; Ashton, Nicholas J.
; Pesini, Pedro
; Sarasa, Leticia
and Allué, José Antonio
, et al. (More)
- Janelidze, Shorena
LU
; Palmqvist, Sebastian
LU
; Leuzy, Antoine
LU
; Stomrud, Erik
LU
; Verberk, Inge M.W.
; Zetterberg, Henrik
LU
; Ashton, Nicholas J.
; Pesini, Pedro
; Sarasa, Leticia
; Allué, José Antonio
; Teunissen, Charlotte E.
; Dage, Jeffrey L.
; Blennow, Kaj
LU
; Mattsson-Carlgren, Niklas
LU
and Hansson, Oskar
LU
(Less)
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, amyloid, Aβ42/Aβ40, blood biomarkers, neurofilament light, p-tau217
- in
- Alzheimer's and Dementia
- volume
- 18
- issue
- 2
- pages
- 283 - 293
- publisher
- Wiley
- external identifiers
-
- scopus:85108291395
- pmid:34151519
- ISSN
- 1552-5260
- DOI
- 10.1002/alz.12395
- language
- English
- LU publication?
- yes
- id
- 533c004f-37a4-485b-85a0-19ac277d1371
- date added to LUP
- 2021-07-12 14:22:05
- date last changed
- 2024-06-16 16:02:01
@article{533c004f-37a4-485b-85a0-19ac277d1371,
abstract = {{<p>Introduction: We studied usefulness of combining blood amyloid beta (Aβ)42/Aβ40, phosphorylated tau (p-tau)217, and neurofilament light (NfL) to detect abnormal brain Aβ deposition in different stages of early Alzheimer's disease (AD). Methods: Plasma biomarkers were measured using mass spectrometry (Aβ42/Aβ40) and immunoassays (p-tau217 and NfL) in cognitively unimpaired individuals (CU, N = 591) and patients with mild cognitive impairment (MCI, N = 304) from two independent cohorts (BioFINDER-1, BioFINDER-2). Results: In CU, a combination of plasma Aβ42/Aβ40 and p-tau217 detected abnormal brain Aβ status with area under the curve (AUC) of 0.83 to 0.86. In MCI, the models including p-tau217 alone or Aβ42/Aβ40 and p-tau217 had similar AUCs (0.86–0.88); however, the latter showed improved model fit. The models were implemented in an online application providing individualized risk assessments (https://brainapps.shinyapps.io/PredictABplasma/). Discussion: A combination of plasma Aβ42/Aβ40 and p-tau217 discriminated Aβ status with relatively high accuracy, whereas p-tau217 showed strongest associations with Aβ pathology in MCI but not in CU.</p>}},
author = {{Janelidze, Shorena and Palmqvist, Sebastian and Leuzy, Antoine and Stomrud, Erik and Verberk, Inge M.W. and Zetterberg, Henrik and Ashton, Nicholas J. and Pesini, Pedro and Sarasa, Leticia and Allué, José Antonio and Teunissen, Charlotte E. and Dage, Jeffrey L. and Blennow, Kaj and Mattsson-Carlgren, Niklas and Hansson, Oskar}},
issn = {{1552-5260}},
keywords = {{Alzheimer's disease; amyloid; Aβ42/Aβ40; blood biomarkers; neurofilament light; p-tau217}},
language = {{eng}},
number = {{2}},
pages = {{283--293}},
publisher = {{Wiley}},
series = {{Alzheimer's and Dementia}},
title = {{Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau}},
url = {{http://dx.doi.org/10.1002/alz.12395}},
doi = {{10.1002/alz.12395}},
volume = {{18}},
year = {{2022}},
}